Biohaven Ltd.
BHVNNYSE
$15.44
↑ +9.0%Jul 17 close · end-of-day
Price
1Y↑ +15.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.3B
Enterprise Value
$1.9B
P/E
—
P/S
—
P/B
17.6
EV/EBITDA
—
PEG
—
FCF Yield
-26.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$647.7M
Free Cash Flow (TTM)
-$594.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-500.1%
ROIC
—
Debt / Equity
—
Net Cash
$347.8M
Return 1Y
+2.2%
Company profile
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
- CEO
- Vladimir Coric
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Connecticut
- Website
- biohavenpharma.com
Management & directors
- Buten MatthewChief Financial Officer
- Car BruceChief Scientific Officer
- Clark George C.VP, Chief Accounting Officer
- Coric VladChief Executive Officer
- Gentile KimberlySVP, Clinical Operations
Roles derived from SEC Form 4 filings.
Earnings
BHVN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.88↓ -59.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$114.5M | -$218.9M | -$567.9M | -$436.1M | -$885.1M | -$745.4M |
| Net income | -$118.7M | -$213.8M | -$570.3M | -$408.2M | -$846.4M | -$738.8M |
| Diluted EPS | -$3.01 | -$5.43 | -$12.75 | -$5.73 | -$9.28 | -$6.86 |
| Operating cash flow | -$76.0M | -$145.8M | -$297.7M | -$331.7M | -$582.5M | -$609.4M |
| Free cash flow | -$77.1M | -$146.8M | -$303.8M | -$334.8M | -$586.5M | -$610.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$333.8M | -$178.2M | -$189.9M | -$221.6M | -$211.7M | -$169.4M | -$142.7M | -$130.4M |
| Net income | -$319.8M | -$160.3M | -$186.8M | -$221.7M | -$198.1M | -$173.4M | -$145.6M | -$130.5M |
| Diluted EPS | -$3.64 | -$1.70 | -$1.74 | -$2.17 | -$1.94 | -$1.64 | -$1.11 | -$0.88 |
| Operating cash flow | -$167.8M | -$141.3M | -$170.7M | -$165.1M | -$167.9M | -$145.7M | -$130.7M | -$149.9M |
| Free cash flow | -$170.7M | -$141.9M | -$170.8M | -$165.6M | -$168.2M | -$145.7M | -$130.7M | -$149.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-17 | Mehta Kishan | Gift | 17,342 | $0.00 | $0.00 | filing |
| 2026-03-17 | Mehta Kishan | Gift | 17,342 | $0.00 | $0.00 | filing |
| 2026-01-05 | Coric Vlad· Chief Executive Officer | Tax withholding | 7,430 | $9.93 | $73,779.90 | filing |
| 2026-01-05 | Buten Matthew· Chief Financial Officer | Tax withholding | 2,594 | $9.93 | $25,758.42 | filing |
| 2026-01-05 | Car Bruce· Chief Scientific Officer | Tax withholding | 2,381 | $9.93 | $23,643.33 | filing |
| 2026-01-05 | Gentile Kimberly· SVP, Clinical Operations | Tax withholding | 1,956 | $9.93 | $19,423.08 | filing |
| 2026-01-05 | Clark George C.· VP, Chief Accounting Officer | Tax withholding | 1,117 | $9.93 | $11,091.81 | filing |
| 2026-01-05 | Car Bruce· Chief Scientific Officer | Option exercise | 4,750 | $0.00 | $0.00 | filing |
| 2026-01-05 | Gentile Kimberly· SVP, Clinical Operations | Option exercise | 3,750 | $0.00 | $0.00 | filing |
| 2026-01-05 | Buten Matthew· Chief Financial Officer | Option exercise | 4,250 | $0.00 | $0.00 | filing |
| 2026-01-05 | Coric Vlad· Chief Executive Officer | Option exercise | 14,250 | $0.00 | $0.00 | filing |
| 2026-01-05 | Clark George C.· VP, Chief Accounting Officer | Option exercise | 2,500 | $0.00 | $0.00 | filing |
| 2025-11-17 | Clark George C.· VP, Chief Accounting Officer | Buy | 17,000 | $8.52 | $144,770.30 | filing |
| 2025-11-13 | CHILDS JOHN W | Buy | 3,333,333 | $7.50 | $25.0M | filing |
| 2025-11-13 | Bailey Gregory | Buy | 400,000 | $7.50 | $3.0M | filing |
| 2025-11-13 | Coric Vlad· Chief Executive Officer | Buy | 333,333 | $7.50 | $2.5M | filing |
| 2025-11-13 | Coric Vlad· Chief Executive Officer | Buy | 333,333 | $7.50 | $2.5M | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.